Our National Meeting week in Washington, D.C. kicked off with our Dancing with Venture event on Monday afternoon, connecting member small and medium-sized companies with venture capitalists in the #lifesciences. In addition to pitches from our SMM community and introductions from investors, the event featured fascinating perspectives and insights from our SMM panel discussion, fireside chat, and managing cash flow session. Thank you to our SMM panelists Nicole Merli, MBA, CRA (LumaCyte), Alina Alexeenko (LyoWave, Inc.), Erica Dawson (InDevR, Inc.), and Lena Wu (Phizzle), our Fireside Chat participants Daniella Kranjac (AVANT BIO) and John Bagdonas, CEP, FGE, NDEF (J.P. Morgan), and managing cash flow speakers Fletcher King and James Fitzgerald (Morgan Stanley), as well as our opening speaker Jorge Lamboy, PhD (National Institute of Standards and Technology (NIST) #biotech #biopharmaceuticals #biomanufacturing
NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals’ Post
More Relevant Posts
-
CEO | Biotech & Life Science | Strategy, Portfolio Management, Business Development and Commercialization.
Join our webinar coming up this week!
Join our webinar this week for expert insights, strategies, and deal-making tips tailored for Biotech Company Executives and Investors. Don't miss this chance to enhance your fundraising skills and engage investors effectively. Feel free to share this invitation with your network and colleagues who might benefit from this enriching experience. #biotechnology #investments #venturecapital #dealmaking #clinicaldevelopment #drugdiscovery #clinicalresearch Bios Health Group
-
-
🎉 Supporting Pharmaceutical Excellence: Tailored Quality Management Solutions for Regulatory Compliance
Reposting my morning post with a more legible article. 😁 Having spent the last week attending AusBiotech, I have had the opportunity to listen to various insights and thoughts on current biotech trends, successes and challenges. I decided to compile my learning and share with my network. So, here is an article summarising my thoughts on why the biotech industry needs to step outside the box for successful drug development. Thank you to all the speakers and panellists who generously and openly shared their experiences and knowledge with the participants. It was great to hear from investors, scientists and industry stakeholders and understand their point of view. #lifescience #biotech #drugdevelopment #qualitysystems #venturecapital
-
Join our webinar this week for expert insights, strategies, and deal-making tips tailored for Biotech Company Executives and Investors. Don't miss this chance to enhance your fundraising skills and engage investors effectively. Feel free to share this invitation with your network and colleagues who might benefit from this enriching experience. #biotechnology #investments #venturecapital #dealmaking #clinicaldevelopment #drugdiscovery #clinicalresearch Bios Health Group
-
-
🌟 New Insights! 🌟 Don't miss Wilson Sonsini Goodrich & Rosati's latest Quarterly Life Sciences Report. This detailed analysis highlights the trends, key insights and developments in biotech and life sciences. LaunchBio's mission is to empower life sciences startups and foster an environment for innovation, and Wilson Sonsini's report is a great resource for anyone looking to stay informed about the current landscape and future directions in life sciences. Check it out below ⬇ #LifeSciences #Biotech #LaunchBio #WilsonSonsini #WSLifeSciReport
This latest edition of our Life Sciences Report is out! The June issue features articles on #biotech client Siolta Therapeutics, the use of safety and efficacy findings to extend drug exclusivity periods, #lifesciences venture financings for clients in 2023, and updated USPTO guidance for determining non-obviousness. The newsletter also includes details on the recent LaunchBio Inc. NextGen VC Forum in San Francisco, the firm’s Patents and Innovations Learning Library for in-house IP counsel, the latest episodes of the LaunchBio/Wilson Sonsini NextGen VC Podcast focused on life sciences investing, and the firm’s sponsorship of the National Inventors Hall of Fame Induction Ceremony, as well as select life sciences client highlights. Read it in full at: https://lnkd.in/eDxpjxp6 #WSLifeSci
-
-
Epoch 23: Private Biotech Capital Allocation Trends 👉Favored therapeutic areas by investors 👉Which modalities are attracting capital 👉Guess which stages of development investors prefer? https://lnkd.in/dEkBy2bY
-
-
I help biopharma executives & investors build C-level relationships in the U.S., Europe, and Asia.
This one is a doozy -> Latest episode of The BioCentury Show with Bob Nelsen of ARCH Venture Partners. ✅ Watch: https://lnkd.in/d3xptP9H (YouTube) Several topics Bob discusses with my BioCentury Inc. colleague Steve Usdin: ➣ Where #AI will impact drug development (and where it won't). ➣ How to build #biotechs for the long-run. ➣ Where Arch finds CEOs for the biotechs it creates. ➣ Which funds Bob likes to co-invest with (and which he doesn't). ➣ The risks of unintended consequences, from the #IRA to the latest #China biotech bills. ➣ What topic Bob wants to discuss most with Sen. Bernie Sanders. ➣ And much more... Plus, a special guest appearance from Bob's cat! It is a great episode: No holds barred. Check it out today. #venturecapital #drugdevelopment #biopharma #drugpricing #BioCenturyShow #geopolitics
-
-
Advancing the science of healthcare and biotechnology is not only a long, complicated pursuit; it is also expensive. No one knows this better than firms increasingly tapping equity market for new capital around research development and product launches. According to Dealogic, biotech has provided a bonanza of follow-on activity over the years. So far in 2023, there has already been USD 3.2bn of follow-on activity from European bio-tech firms, including on non-European exchanges, more than the entire 2022 USD 2.6bn: https://lnkd.in/ehnzyYgV
-
-
Check out our latest life sciences report, with trends in recent life sciences deal activity.
This latest edition of our Life Sciences Report is out! The June issue features articles on #biotech client Siolta Therapeutics, the use of safety and efficacy findings to extend drug exclusivity periods, #lifesciences venture financings for clients in 2023, and updated USPTO guidance for determining non-obviousness. The newsletter also includes details on the recent LaunchBio Inc. NextGen VC Forum in San Francisco, the firm’s Patents and Innovations Learning Library for in-house IP counsel, the latest episodes of the LaunchBio/Wilson Sonsini NextGen VC Podcast focused on life sciences investing, and the firm’s sponsorship of the National Inventors Hall of Fame Induction Ceremony, as well as select life sciences client highlights. Read it in full at: https://lnkd.in/eDxpjxp6 #WSLifeSci
-
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Vilya raises $21M in Series A extension; Shionogi to build research center in San Diego >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #healthcare #biotech
-
Thoughts on this? >> Vilya raises $21M in Series A extension; Shionogi to build research center in San Diego >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #biotech #healthcare #pharma
Vilya raises $21M in Series A extension; Shionogi to build research center in San Diego
https://endpts.com
Board Director | Strategic Advisor | CEO | Biotech & Analytical Tools Founder | Business/Corp Development
2wGreat Discussion with Great Panelists!